Rubin Eyal 4/A
4/A · Protalix BioTherapeutics, Inc. · Filed Nov 5, 2024
Insider Transaction Report
Form 4/AAmended
Rubin Eyal
Sr. VP & CFO
Transactions
- Award
Common Stock
2024-09-23+90,909→ 660,909 total(indirect: By Trust)
Footnotes (3)
- [F1]The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted.
- [F2]Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.
- [F3]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.